BNF 84 (British National Formulary) September 2022-March 2023: 84: September 2022 - March 2023

Product Information

BNF 81 New drug monographs: Cefiderocol (Fetcroja), Bempedoic acid (Nilemdo), Solriamfetol (Sunosi) Physicochemical Principles of Pharmacy in Manufacture, Formulation and Clinical Use - 6th ed. (2016) MD5 of a better version of this file (if applicable). Fill this in if there is another file that closely matches this file (same edition, same file extension if you can find one), which people should use instead of this file. If you know of a better version of this file outside of Anna’s Archive, then please upload it.

This is amazing! Who knew we had access to all of these books? Very pleased with this unexpected benefit for members.” June 2022 Correction of side-effect content in BNF monographs for cetuximab, lenvatinib and regorafenib For each vaccine monograph, the Drug action section includes a short summary of the vaccine type. Detailed information on the vaccine’s mechanism of action can be found in the corresponding Treatment summaries. The classifications, which are used to group similar vaccines, have also been updated.Joint Formulary Committee (2021) 'Paracetamol', in British National Formulary. Available at: https://www-medicinescomplete-com.apollo.worc.ac.uk/#/content/bnf/_970446495(Accessed: 21July2022). The BNF is authored by the Joint Formulary Committee and you can access it via our Medicines Complete subscription. Vaccine monographs in the BNF and BNF for Children have been updated to more clearly identify whether a vaccine is live or not. New and updated treatment summaries: Genital system infections, antibacterial therapy, Venous thromboembolism Ideal for use by Pharmacists, Chemists, Nurses and Doctors within Hospitals, Nursing Homes, Pharmacies and Hospices and the ideal reference tool for all Care and support staff. See also:

In drug monographs that contain two or more drugs, the BNF includes cross references to the single ingredient monographs to help the user locate all information about the drugs contained in the combination product. A British National Formulary (BNF) is a medical and pharmaceutical publication that contains information and advice on prescribing and pharmacology, along with specific facts and details about all medicines available on the NHS. The interactions are displaying correctly when the interactions information is accessed directly via links from the Interactions section of the co-drug monographs in BNF and BNF for Children. Specialist drug monographs: inclusion of the words “Specialist drug” alongside the monograph title to identify drugs used within specialist settings (such as drugs used for malignancy, and those given via intravitreal injection). These monographs continue to include information to support patient safety and non-specialist patient care (such as important safety information, interactions, side-effects, and contra-indications) but no longer include information which is within the remit of specialist care (such as doses, and directions for administration). Ibrutinib (Imbruvica®): new risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac eventsFrom June 2023, BNF Publications will be more clearly and consistently identifying specialist drug monographs within content, by including the words “Specialist drug” alongside the monograph title. This feature will be applied to existing monographs, and to monographs moving forward, that are used within specialist settings (such as drugs used for malignancy, and those given via intravitreal injection). These “specialist drug” monographs will contain less detail than a regular monograph within BNF Publications. A “specialist drug” monograph will continue to include information to support patient safety and non-specialist patient care (such as important safety information, interactions, side-effects, and contra-indications), but it will not contain information which is within the remit of specialist care (such as doses, and directions for administration). Please note that co-trimoxazole currently has its own entry in print that does not include the interactions for trimethoprim. As stated above, it is essential to refer to both drugs (trimethoprim and sulfamethoxazole, under sulfonamides) to find all relevant interactions for this drug. This inconsistency will be corrected in the upcoming September editions, BNF 78 and BNF for Children 2019-2020. Digital products including MedicinesComplete and the BNF app have been corrected for the June monthly update. BNF 83 New drug monographs: Estradiol with progesterone (Bijuve), Molnupiravir (Lagerviro), Inclisiran (Leqvio), Vericiguat (Verquvo), Relugolix with estradiol and norethisterone acetate (Ryeqo) Please report metadata errors at the source library. If there are multiple source libraries, know that we pull metadata from top to bottom, so the first one might be sufficient.

The valganciclovir drug monograph in BNF for Children has incorrectly included the following equivalence statement since the monograph was added for the July 2018 monthly digital update and the print edition BNF for Children 2018-2019. Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice] Completely free for members, our e-Library contains over 100 essential pharmacy e-Book texts curated by our professionallibrarian, as well as: The results of this research have enabled us to critically review the information that should be included within specialist drug monographs. “Specialist drug” monographs will contain less detail than a regular monograph within BNF Publications, in a consistent format. A “specialist” monograph will continue to include information to support patient safety and non-specialist patient care (such as important safety information, interactions, side-effects, and contra-indications), but it will not contain information which is within the remit of specialist care (such as doses, and directions for administration). The current level of additional prescribing information has been retained for drug monographs that have a mix of specialist and non-specialist uses (such as methotrexate that is used for both malignancy and rheumatological conditions). At Medicalstudyzone.com, we take user experience very seriously and thus always strive to improve. We hope that you people find our blog beneficial!

BNF 84 New drug monographs: Icosapent ethyl (▼Vazkepa), Baloxavir marboxil (▼Xofluza), Herpes-zoster vaccine [recombinant, adjuvanted] (▼Shingrix) If you’re a UK-based individual undertaking work or training for the NHS, you can register for access to BNF content on MedicinesComplete. As a registered NHS user, you’ll get single user access to BNF and BNF for Children content on MedicinesComplete for 365 days.